C Cure 709

Drug Profile

C Cure 709

Alternative Names: C-709; C-Cure 709; Genetically modified cytotoxic T lymphocyte - CellCure

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator CellCure A/S
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Malignant-melanoma in Denmark (Intratumoural, Injection)
  • 15 Feb 2006 Final results from a phase I clinical trial in patients with metastatic Melanoma have been added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top